• OTS
  • July 31, 2018
SHARE
Post Views: 815

Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN.
CPT Pharmacometrics Syst Pharmacol. 2018 Jul 24.

PubMed

Related articles

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma

April 23rd, 2021
Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

Super-resolution RNA imaging using a rhodamine-binding aptamer with fast exchange kinetics

March 15th, 2021
Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology

February 16th, 2021
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

January 30th, 2021
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease

January 30th, 2021
The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration

January 30th, 2021